Premium
A COMPARISON BETWEEN BC 105 AND METHYSERGIDE IN THE PROPHYLAXIS OF MIGRAINE
Author(s) -
Forssman B.,
Henriksson K.G.,
Kihlstrand S.
Publication year - 1972
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1972.tb07541.x
Subject(s) - methysergide , migraine , headaches , medicine , anesthesia , ergotamine , vasoconstriction , surgery , serotonin , receptor
A double‐blind cross‐over study has been performed in order to evaluate the effectiveness of BC 105 compared with Methysergide in preventing attacks of migraine. The drugs were given for ten weeks each. In order to avoid rebound effects, only the last six weeks of each treatment period were taken into account, and the results during these periods were compared with an initial six‐week period during which no prophylactic drugs were given. The results are based on evaluation of data from 16 patients with classical or common migraine and one patient with cluster headache. We found that BC 105 and Methysergide both decrease the frequency of headaches significantly and there is no significant difference between their effects. No serious side‐effects were noted in this short‐term study. The most commonly encountered side‐effects in patients taking BC 105 were drowsiness, mostly transitory, increased appetite, and weight gain. Laboratory studies and physical examinations did not detect any disturbances in blood count, or in kidney, liver or heart functions. No symptoms or signs of vasoconstriction were recorded.